US 7355012
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
granted A61KA61K2039/505A61K47/6829
Quick answer
US patent 7355012 (Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of the Department of Health and Human Services
- Grant date
- Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K2039/505, A61K47/6829, A61K47/6849, A61K47/6875